Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Mastocytosis 4Recurrence 2Pruritus 2Piebaldism 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Mastocytosis, Systemic 2Gastrointestinal Stromal Tumors 2Blushing 2Ovarian Neoplasms 1Metastatic Castrate Resistant Prostate Cancer 1Melanoma 1Gastro-intestinal Stromal Tumours 1Gastro-Intestinal Stromal Tumour 1Gastro Intestinal Stromal Tumor 1Colorectal Neoplasms 1Colorectal Cancer Metastatic 1

Interventions

Bevacizumab 19Capecitabine 15Oxaliplatin 11Irinotecan 11Cetuximab 11Fluorouracil 10Leucovorin 8aflibercept 7Panitumumab 6trifluridine tipiracil drug combination 4Nivolumab 4sintilimab 3regorafenib 3Ipilimumab 3Vemurafenib 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Folfox protocol 2Drug Therapy 2tremelimumab 1spartalizumab 1raltitrexed 1pembrolizumab 1monoclonal antibody YYB-101 1masitinib 1irinotecan sucrosofate 1glucopyranosyl lipid-A 1folfirinox 1durvalumab 1camrelizumab 1balstilimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colorectal Cancer Metastatic × masitinib × Clear all
NCT03556956 2020-12-08

Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer

AB Science

Phase 2/3 Completed
219 enrolled
Gastrointestinal

Colorectal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡